AlphAIalphai — Financial news for AI agents
prnewswire.comSEP 32 min read$REGN

REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Fraud Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure

Regeneron Pharmaceuticals (REGN) faces a securities class action lawsuit over alleged misrepresentations regarding a Phase 3 clinical trial for a melanoma treatment. The trial's failure caused a $11B market cap drop, prompting the lawsuit. Investors who bought shares between Aug. 1, 2025, and May 15, 2026, may be affected. The firm Hagens Berman is investigating.

Original reporting
prnewswire.com
Published Sep 3, 2026, 7:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Fraud Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure — source image
Source · prnewswire.com
Decision brief

The 30-second read

$REGNBearishLow
01

Why it matters

The disclosure caused a sharp share decline and a $11 billion market‑cap loss, raising concerns about regulatory and legal exposure.

02

Market read

The lawsuit underscores the risk of trial failures in biotech and may trigger broader sector caution.

03

What to watch

Possible settlement negotiations or insurance recoveries could mitigate the financial hit.

Relevance 8/10Novelty 8/10Timing: Sept 3 2026 (today)

Background

Regeneron announced a failed Phase 3 melanoma trial, prompting a class‑action lawsuit alleging misleading statements about trial protocol and results.

Company-level read

Ticker impact

$REGNBearishHigh confidence
Context

Regeneron faces a securities class action after its Phase 3 melanoma trial failed, wiping out $11 billion in market value.

Expected impact

Further downside pressure as investors assess legal exposure and trial failure.

Evidence & confidence

Legal risk and failed trial are material, with a large market-cap impact and ongoing litigation.

Market effects

Sector

Biotech sector may see heightened scrutiny of trial disclosures and increased volatility.

Regional

U.S. biotech stocks could face short‑term pressure as investors reassess trial risk.

Global

Potential ripple effects on global pharma investors monitoring trial integrity.

Counterpoint

What could challenge this read

If the trial data can be salvaged in a later analysis, the stock may rebound once legal costs are clarified.

Key entities

  • company
    Regeneron Pharmaceuticals, Inc.

    Biotech firm developing melanoma therapy.

  • law_firm
    Hagens Berman Sobol Shapiro LLP

    Plaintiff law firm filing the securities class action.

Read at source← All news

Related articles

SEP 2
$REGNMedAI 8/10

Regeneron Pharmaceuticals stock hits 52-week high at $847.60

Regeneron Pharmaceuticals (REGN) hit a 52-week high of $847.60, up 50.05% over the past year. The stock trades at $847.19, 32% below its InvestingPro Fair Value of $1,118. Q2 2026 earnings were $14.29 per share, with revenue of $4.29 billion, up 17% YoY. Analysts raised price targets, with BofA Securities at $891 and Bernstein SocGen at $756.

investing.com2 min
AUG 31
$REGNMedAI 8/10

Is Pasatru’s Rare Disease Approval With Home Infusion Potential Altering The Investment Case For Regeneron Pharmaceuticals (REGN)?

Regeneron Pharmaceuticals (REGN) received FDA approval for Pasatru (garetosmab-grts), a new rare disease therapy for fibrodysplasia ossificans progressiva. The drug can be infused at home and showed strong lesion-reduction results. Analysts discuss its impact on Regeneron's investment case, with projections of $19.4B revenue and $6.0B earnings by 2029. Pasatru adds to Regeneron's portfolio but EYLEA's performance remains a key focus.

simplywall.st3 min
AUG 29
$REGNMedAI 9/10

Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOP

Regeneron Pharmaceuticals (REGN) received FDA approval for Pasatru to treat adults with fibrodysplasia ossificans progressiva, based on positive Phase 3 trial results. The approval adds a new rare disease therapy to Regeneron's portfolio, potentially diversifying revenue streams. REGN has a market cap of US$80.7b and focuses on immunology and genetic medicine.

yahoo.com2 min
AUG 28
$REGNHighAI 9/10

Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 14, 2026 Lead Plaintiff Deadline

Regeneron Pharmaceuticals (REGN) faces a securities class action lawsuit after a Phase 3 clinical trial for a melanoma treatment failed, causing a $11B market cap wipeout. The lawsuit alleges Regeneron misled investors about the trial's prospects between August 2025 and May 2026. Investors with losses before the September 2026 deadline are urged to contact Hagens Berman.

prnewswire.com2 min
AUG 27
$REGNMedAI 8/10

Can Regeneron (REGN)’s Rare-Disease Win Move the Earnings Needle?

The FDA approved Regeneron's (REGN) Pasatru for fibrodysplasia ossificans progressiva, a rare disease. The drug showed a 94% reduction in new bone lesions in a Phase 3 trial. Regeneron's Q2 revenue was $4.29B, up 17%, with strong sales from Dupixent and Eylea HD. Pasatru's market potential is limited due to the disease's rarity, but it validates Regeneron's research platform.

finance.yahoo.com2 min
AUG 27
$REGNHighAI 8/10

REGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and certain officers, alleging securities law violations. The lawsuit covers investors who acquired Regeneron securities between August 1, 2025, and May 15, 2026, claiming misleading statements about a Phase III study.

accessnewswire.com1 min